Skip to main content
SpringerLink
Log in

Omalizumab wirkt gegen bullöses Pemphigoid

  • Literatur kompakt
  • Published:
hautnah dermatologie Aims and scope

In einer kleinen, offenen und unkontrollierten Studie haben US-Mediziner untersucht, ob sich der monoklonale Anti-IgE-Antikörper Omalizumab für die Therapie des bullösen Pemphigoids eignet.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  • Yu KK et al. Omalizumab therapy for bullous pemphigoid. J Am Acad Dermatol 2014 Jun 20

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Robert Bublak

Authors
  1. Robert Bublak
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bublak, R. Omalizumab wirkt gegen bullöses Pemphigoid. hautnah dermatologie 30, 19 (2014). https://doi.org/10.1007/s15012-014-1878-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15012-014-1878-1

Search

Navigation